Saudi Chemical Holding Past Earnings Performance
Past criteria checks 5/6
Saudi Chemical Holding has been growing earnings at an average annual rate of 7.2%, while the Healthcare industry saw earnings growing at 11.9% annually. Revenues have been growing at an average rate of 8.2% per year. Saudi Chemical Holding's return on equity is 10.2%, and it has net margins of 3.8%.
Key information
7.2%
Earnings growth rate
7.2%
EPS growth rate
| Healthcare Industry Growth | 12.3% |
| Revenue growth rate | 8.2% |
| Return on equity | 10.2% |
| Net Margin | 3.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
With EPS Growth And More, Saudi Chemical Holding (TADAWUL:2230) Makes An Interesting Case
Mar 06
Saudi Chemical Holding Company's (TADAWUL:2230) 26% Jump Shows Its Popularity With Investors
Feb 10Saudi Chemical Holding (TADAWUL:2230) Is Reinvesting At Lower Rates Of Return
Oct 31Here's Why We Think Saudi Chemical Holding (TADAWUL:2230) Might Deserve Your Attention Today
Jul 06Saudi Chemical Holding (TADAWUL:2230) Is Due To Pay A Dividend Of SAR0.50
Jan 09Saudi Chemical Holding (TADAWUL:2230) Has Affirmed Its Dividend Of SAR0.50
Dec 22Here's What's Concerning About Saudi Chemical Holding's (TADAWUL:2230) Returns On Capital
Sep 14Saudi Chemical Holding (TADAWUL:2230) Will Be Hoping To Turn Its Returns On Capital Around
Dec 06Does It Make Sense To Buy Saudi Chemical Holding Company (TADAWUL:2230) For Its Yield?
Apr 19Here's What's Concerning About Saudi Chemical's (TADAWUL:2230) Returns On Capital
Mar 29Is Saudi Chemical Company's (TADAWUL:2230) 2.8% ROE Worse Than Average?
Mar 01Does Saudi Chemical's (TADAWUL:2230) Share Price Gain of 41% Match Its Business Performance?
Feb 01
How Has Saudi Chemical (TADAWUL:2230) Allocated Its Capital?
Dec 28Should You Be Concerned About Saudi Chemical Company's (TADAWUL:2230) ROE?
Nov 30Revenue & Expenses BreakdownBeta
How Saudi Chemical Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,855 | 183 | 356 | 0 |
| 30 Sep 23 | 4,521 | 117 | 358 | 0 |
| 30 Jun 23 | 4,081 | 93 | 337 | 0 |
| 31 Mar 23 | 3,831 | 80 | 322 | 0 |
| 31 Dec 22 | 3,696 | 80 | 310 | 0 |
| 30 Sep 22 | 3,378 | 51 | 295 | 0 |
| 30 Jun 22 | 3,402 | 48 | 285 | 0 |
| 31 Mar 22 | 3,346 | 61 | 292 | 0 |
| 31 Dec 21 | 3,411 | 70 | 290 | 0 |
| 30 Sep 21 | 3,491 | 53 | 264 | 0 |
| 30 Jun 21 | 3,517 | 64 | 270 | 0 |
| 31 Mar 21 | 3,476 | 77 | 259 | 0 |
| 31 Dec 20 | 3,306 | 74 | 267 | 0 |
| 30 Sep 20 | 3,066 | 46 | 328 | 0 |
| 30 Jun 20 | 2,991 | 41 | 340 | 0 |
| 31 Mar 20 | 2,909 | 32 | 342 | 0 |
| 31 Dec 19 | 2,949 | 33 | 334 | 0 |
| 30 Sep 19 | 3,226 | 101 | 301 | 0 |
| 30 Jun 19 | 3,120 | 101 | 280 | 0 |
| 31 Mar 19 | 2,998 | 98 | 263 | 0 |
| 31 Dec 18 | 2,949 | 115 | 245 | 0 |
| 30 Sep 18 | 2,768 | 128 | 220 | 0 |
| 30 Jun 18 | 2,650 | 143 | 211 | 0 |
| 31 Mar 18 | 2,541 | 143 | 209 | 0 |
| 31 Dec 17 | 2,474 | 142 | 211 | 0 |
| 30 Sep 17 | 2,274 | 129 | 196 | 0 |
| 30 Jun 17 | 2,206 | 119 | 196 | 0 |
| 31 Mar 17 | 2,279 | 138 | 197 | 0 |
| 31 Dec 16 | 2,143 | 134 | 194 | 0 |
| 30 Sep 16 | 2,258 | 168 | 212 | 0 |
| 30 Jun 16 | 2,303 | 185 | 210 | 0 |
| 31 Mar 16 | 2,320 | 216 | 210 | 0 |
| 31 Dec 15 | 2,410 | 251 | 207 | 0 |
| 30 Sep 15 | 2,413 | 266 | 190 | 0 |
| 30 Jun 15 | 2,452 | 270 | 196 | 0 |
| 31 Mar 15 | 2,470 | 279 | 187 | 0 |
| 31 Dec 14 | 2,484 | 284 | 186 | 0 |
| 30 Sep 14 | 2,566 | 292 | 189 | 0 |
| 30 Jun 14 | 2,450 | 313 | 172 | 0 |
| 31 Mar 14 | 2,359 | 303 | 169 | 0 |
| 31 Dec 13 | 2,275 | 301 | 163 | 0 |
| 30 Sep 13 | 2,236 | 292 | 162 | 0 |
| 30 Jun 13 | 2,163 | 282 | 164 | 0 |
Quality Earnings: 2230 has high quality earnings.
Growing Profit Margin: 2230's current net profit margins (3.8%) are higher than last year (2.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2230's earnings have grown by 7.2% per year over the past 5 years.
Accelerating Growth: 2230's earnings growth over the past year (128%) exceeds its 5-year average (7.2% per year).
Earnings vs Industry: 2230 earnings growth over the past year (128%) exceeded the Healthcare industry 23.9%.
Return on Equity
High ROE: 2230's Return on Equity (10.2%) is considered low.